Picture of Hyperion DeFi logo

HYPD — Hyperion DeFi News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Eyenovia to discontinue late-stage study for eye drug (updated)

(Adds details throughout)
       Nov 15 (Reuters) - Eyenovia  EYEN.O  said on Friday it
would terminate a late-stage study for its experimental
drug-device combination to treat an eye disease after failing
the main goal of slowing the progression of the condition.
    The disease, called pediatric progressive myopia, causes
near-sightedness in early childhood, which worsens as the person
grows.
    An independent committee reviewed the safety and efficacy
data from 252 trial participants and found that the rate of
myopia progression was not significantly different between the
treatment arm and placebo.
    The drug developer said it plans to review the data more
thoroughly and evaluate strategic alternatives, including a
business combination, reverse merger and/or sale of assets.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi
Majumdar)
 ((Mariam.ESunny@thomsonreuters.com))

Recent news on Hyperion DeFi

See all news